All Oncology News

Anees B. Chagpar, MD, shares her thoughts on the final US Preventive Services Task Force guidelines and how they change the focus of breast cancer screening.

Thoracic specialist will guide expansion of clinical programs, integrate research into patient care.

Patricia M. LoRusso, D.O. was among a group of 15 top cancer researchers and physician-scientists who met in Washington with aides to Vice President Joe Biden on Jan. 8 to discuss his “moonshot” program to advance cancer treatment.

A fresh study of the much exploited 340B Drug Discount Program says that draft guideline revisions under consideration would likely not be successful because the Health Resource and Services Administration does not have the statutory authority to impose or to enforce them.

The VEGFR inhibitor pazopanib was efficacious independent of T-cell receptor–gamma entropy in metastatic renal cell carcinoma setting.

Pamela L. Kunz, MD, discusses several recent studies that shown promise for the treatment of pancreatic neuroendocrine tumors (NETs), as well as other ongoing trials investigating the potential of immunotherapies in NETs.

OncLive® welcomes the University of Vermont Cancer Center to its Strategic Alliance Partnership for promoting public awareness of the latest advances in cancer research and care.

New collaboration to publicize advances in cancer research and treatment.

The optimal frontline treatment strategy for patients with metastatic renal cell carcinoma could look dramatically different in the next few years, as studies assess combination strategies and predictive biomarkers for immunotherapy and targeted therapies.

Hope Rugo, MD, discusses the phase Ib KEYNOTE-028 trial and the impact of its results thus far, as well as the design, findings, and next steps for the trial.

City of Hope is offering an interactive educational conference for oncologists, hematologists and oncology nurses to learn about the latest advances in bone marrow transplants, as well as the treatment of leukemia, lymphoma and myeloma.

The FDA has assigned a priority review to venetoclax for use in adults with chronic lymphocytic leukemia, including patients with a 17p deletion, following at least 1 prior therapy.

The combination of atezolizumab (MPDL3280A) and vemurafenib (Zelboraf) yielded durable responses in patients with previously untreated BRAF V600–mutated metastatic melanoma in an ongoing phase Ib study.

The US Preventive Services Task Force has issued final guidelines that stand by its recommendation that women at average risk of breast cancer should not start routine screenings until they reach age 50 years and that they should then undergo testing every 2 years.

Jason J. Luke, MD, discusses potential new methods for determining prognostic markers in melanoma and the challenges of balancing toxicity with efficacy in designing combination regimens.

Victoria Atkinson, MD, discusses the impact of the phase III CheckMate-066 trial and nivolumab’s future as both a monotherapy and in combination with other therapies.

Jesus San Miguel, MD, PhD, discusses a phase I study examining pembrolizumab added to lenalidomide and low-dose dexamethasone in patients with heavily pretreated relapsed/refractory multiple myeloma, while emphasizing the need for further follow-up.

Intermittent degarelix administered as described is noninferior to continuous androgen deprivation in maintaining PSA suppression, which indicates that degarelix is a suitable treatment option in men being considered for intermittent androgen ablation.

Jennifer Wu, MD, sheds light on TAS-102, as well as some emerging agents likely to play a role in the treatment of patients with colorectal cancer.

With the development of novel therapies, the role and optimal timing of autologous stem cell transplant for the treatment of multiple myeloma have come into question.

Rutgers Cancer Institute of New Jersey to train the next generation of cancer researchers.

Saad Usmani, MD, discusses newly approved treatments for patients with multiple myeloma, as well as combination therapies currently being investigated in clinical trials.

John L. Marshall, MD, discusses treatment advancements and other ongoing developments in colorectal cancer.

David Reardon, MD, discusses the ReACT study and the potential of rindopepimut and other immunotherapy agents for the treatment of patients with brain cancers, specifically glioblastoma.

The FDA has approved a non-alcohol formulation of docetaxel as a treatment for patients with breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer.

A new drug application has been submitted for cabozantinib as a treatment for patients with advanced renal cell carcinoma who have received one prior therapy.

Grade 3 diarrhea occurred in 16% of patients treated with neratinib and prophylactic loperamide, representing a significant reduction compared with phase III findings from the ExteNET trial.

S. Vincent Rajkumar, MD, discusses a trial of bortezomib, lenalidomide, and dexamethasone versus lenalidomide plus dexamethasone in patients with previously untreated multiple myeloma.

The FDA has granted a breakthrough therapy designation to the third-generation EGFR TKI BI-1482694 as a potential treatment for patients with EGFR T790M-positive non–small cell lung cancer.

Frederick Locke, MD, discusses the potential for KTE-C19 in non-Hodgkin lymphoma.